Business
Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020Results From
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"OV101 (gaboxadol) in Neurodevelopmental Disorders:\n Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET Non-Interventional Data in Fragile X Expected by Early Q2 2020 OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE): Data from Randomized Phase 2 ELEKTRA Trial in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Expected in 2H 2020Initial Data from Phase 2 ARCADE Trial in Dup15q Syndrome or CDKL5 Deficiency Disorder Expected in Q1 2020Additional Clinical Data From ENDYMION Open Label Extension Study Expected in Q1 2020 NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today outlined key clinical and business priorities for 2020. “Our focus in 2019 was on execution, building our senior leadership team and strengthening our balance sheet. As we look ahead to 2020, we enter the year in a strong financial position and will start to realize the potential impact that our hard work can deliver with multiple important clinical data readouts anticipated throughout the year,” said Jeremy Levin, DPhil, MB, BChir, chairman and chief executive officer of Ovid Therapeutics. “We expect new late-stage data from our two lead programs and across multiple indications in 2020. We will report the results of our pivotal Phase 3 NEPTUNE trial which, if successful, would make gaboxadol the first-ever treatment for Angelman syndrome. In addition, we will report data from the Phase 2 ROCKET signal-finding trial in Fragile X syndrome, a program that has the potential to provide a clinical path forward in this poorly served area. Finally, we are very excited to report updated data from soticlestat in rare epilepsies, which we believe could provide a clinically meaningful benefit to these patients who have limited options. 2020 is poised to be a pivotal year for our company and importantly, for the patients and families for which we strive every day to help.” For a full summary of 2020 clinical data milestones, please visit the Investors section of the Ovid Therapeutics website. Clinical Data Readouts Expected in 2020 Gaboxadol for Angelman SyndromeOvi...